by barry101 | Nov 11, 2024 | Press Releases
– On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of R/R AML in Q1 2025 – Median durability of...
by barry101 | Nov 5, 2024 | Press Releases
HOUSTON, Nov. 5, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that...
by barry101 | Nov 4, 2024 | Press Releases
Strong preclinical evidence of Annamycin’s potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON, Nov. 4, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a late stage pharmaceutical company with...
by barry101 | Oct 17, 2024 | Press Releases
Access the transcript here HOUSTON, Oct. 17, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and...
by barry101 | Oct 7, 2024 | Press Releases
Live webcast discussion featuring internationally renowned Acute Myeloid Leukemia (AML) Key Opinion Leaders Ongoing progress of pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) designed for possible accelerated approval of Annamycin in...
by barry101 | Oct 4, 2024 | Press Releases
HOUSTON, Oct. 4, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its...
